Objectives: Helminth
parasites infect over a quarter of the global population and can
profoundly modulate host immunity, potentially influencing vaccine
performance and the spread of pandemic pathogens such as severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite the high global
endemicity of helminth infections, their impact on immune responses to
various COVID-19 vaccines remains unknown. This study aimed to evaluate
the impact of Schistosoma infection on the immunogenicity and protective efficacy of messenger RNA (mRNA)- and protein-based COVID-19 vaccines.Methods: Mice with Schistosoma
infection and non-infected controls were immunized with either an
mRNA-based COVID-19 vaccine or an alum-adjuvanted spike protein vaccine.
Vaccine-induced humoral and cellular immune responses were assessed,
and protective efficacy was evaluated using a SARS-CoV-2 challenge
model.Results: COVID-19 mRNA vaccination induced strong spike-specific antibody and CD4 T-cell responses in Schistosoma-infected
mice comparable to non-infected controls, despite a
Th2/regulatory-biased immune environment, although multifunctional CD8
T-cell responses were reduced. Alum-adjuvanted protein vaccination
elicited robust humoral but weaker cellular immunity, with comparable
immune responses in infected and non-infected mice. Following SARS-CoV-2
challenge, both vaccine platforms conferred effective protection, with
substantial viral clearance and minimal lung pathology.Conclusions: mRNA
and protein vaccines elicit distinct immune profiles; however, both
protect effectively against SARS-CoV-2 infection in mice with concurrent
helminth infection.